Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma

Inclusion Criteria: * Melanoma stage III (regional lymph node recurrence). Will be selected the patients with only one invaded lymph node confirmed by anatomopathological exam after lymph nodes excision. * Absence of visceral metastases verified by physical examination, chest radiography, liver echography and brain-chest-liver CT-Scan. * Age \< 75 years, both genders * ECOG 0-2, Karnofsky \> 80%. * Negative pregnancy test performed at the screening visit for fertile women. * The potentially fertile women must use an oral contraception or an intra-uterine device (IUD) until three months following the last injection of the study treatment. * The patients must have fully recovered from surgery. * HIV 1/2: The patients must be negative for antibodies HIV 1 and HIV 2 and for Ag P24 or DGV HIV. * HBV: The patients must be negative for the antigen, but can be positive for the antibodies but with a negative DNA PCR. * HCV: The patients must be negative for the antibodies. * HTLV ½: The patients must be negative for the antibodies. * Following laboratory results: * Hemoglobin: ≥ 10 g/dl * WBC: ≥ 4000/µl * Lymphocytes: ≥ 700/µl * Platelet count: ≥ 100.000/µl * Serum creatinine: \< 2.0 mg/dl or £ 177 mmol/l * Serum Bilirubin: \< 2.0 mg/dl or £ 34.2 mmol/l * ASAT and ALAT: \< 2.5 x the upper limit of normal. Exclusion criteria: * Patient with more than one invaded lymph node confirmed by anatomopathological exam. * Presence of melanoma metastases discovered by clinical or radiological examination at the screening visit. * Patients must not have received any Chemotherapy, immunotherapy or radiotherapy within the preceding 4 weeks (6 weeks since prior nitrosurea and mitomycin C therapies). * Presence of cardiac affections (congestive cardiac insufficiency, coronaropathy, not controlled HTA). * Any serious active medical illnesses, for example: Active systemic infections requiring of antibiotics, coagulation disorders or any other condition which requires concomitant medications not allowed during this study. * Presence of the second active cancer other than surgically cured non-melanoma skin cancer or cervical carcinoma in-situ. * Any affection requiring a systemic corticotherapy or a treatment by Interferon A. * Any active auto-immune disease including the insulin-dependent diabetes or a immunodeficiency. The vitiligo is not an exclusion criteria. * Thyroid dysfunction not responsive to therapy. * Positive Serology for HIV, HVB, HVC or HTLV1/2. * Woman pregnant or nursing or without an effective contraception. * Incapacity to give written consent.